Compound ID | 895
ABI-0197N
Class: Rifamycin
| Spectrum of activity: | Gram-negative |
| Details of activity: | RNA synthesis inhibitors; aimed for treatment of MRSA |
| Description: | Rothstein DM, Mullin S, Sirokman K, Hazlett C, Doye A, et al. Novel rifamycin derivatives possess good in vivo efficacy in a rifamycin-resistant S. aureus infection model. 44th-ICAAC 2004;206-208 |
| Institute where first reported: | ActivBiotics, Inc., USA |
| Year first mentioned: | 2004 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/349988029 |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.